(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
24 February 2011 (24.02.2011)

PCT

(10) International Publication Number
WO 2011/022063 A1

(51) International Patent Classification:
A01N 37/12 (2006.01) *A61K 31/195* (2006.01)
A01N 37/44 (2006.01)

(21) International Application Number:
PCT/US2010/002283

(22) International Filing Date:
19 August 2010 (19.08.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/274,687 20 August 2009 (20.08.2009) US
61/337,612 11 February 2010 (11.02.2010) US

(71) Applicant *(for all designated States except BB, US)*: **TEVA PHARMACEUTICAL INDUSTRIES LTD.** [IL/IL]; 5 Basel Street, P.o. Box 3190, 49131 Petach-tikva (IL).

(71) Applicant *(for BB only)*: **TEVA PHARMACEUTICALS USA, INC.** [US/US]; 1090 Horsham Road, North Wales, PA 19454 (US).

(72) Inventor; and
(75) Inventor/Applicant *(for US only)*: **KLINGER, Ety** [IL/IL]; 16 Agadati Street, 39930 Tel Aviv (IL).

(74) Agent: **WHITE, John, P.**; Cooper & Dunham LLP, 30 Rockefeller Plaza, New York, NY 10112 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*

WO 2011/022063 A1

(54) **Title**: LOW FREQUENCY GLATIRAMER ACETATE THERAPY

(57) **Abstract**: A method of alleviating a symptom of relapsing-remitting multiple sclerosis in a human patient suffering from relapsing-remitting multiple sclerosis or a patient who has experienced a first clinical episode and is determined to be at high risk of developing clinically definite multiple sclerosis comprising administering to the human patient three subcutaneous injections of a therapeutically effective dose of glatiramer acetate over a period of seven days with at least one day between every subcutaneous injection so as to thereby alleviate the symptom of the patient.